SCHEMBL1235256

SCHEMBL1235256

COC(=O)c1ccc(-c2ccc(C(=O)OC)s2)s1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.60
NPSR1 Q6W5P4 2/20 0.60
PPARG P37231 1/20 0.60
NCOA2 Q15596 1/20 0.60
NCOA1 Q15788 1/20 0.60
NCOA3 Q9Y6Q9 1/20 0.60
HPGD P15428 6/20 0.53
L3MBTL1 Q9Y468 3/20 0.53
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53
ATM Q13315 1/20 0.53
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 4/20 0.46
GLA P06280 2/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.43
TDP1 Q9NUW8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6498557 0.90 DAO (0.52) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL6477476 0.90 KDM4E (0.58) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL23407055 0.89 NPSR1 (0.50) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL19439636 0.89 LMNA (0.50) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL70027 0.88 NPSR1 (0.67) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL20718437 0.86 NPSR1 (0.47) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL31055049 0.86 KDM4E (0.68) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL71536 0.85 RAB9A (0.66) PPARGNCOA2NCOA1NCOA3HPGD
SCHEMBL29906340 0.84 RAB9A (0.51) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL23436971 0.84 NPSR1 (0.46) LMNANPSR1PPARGNCOA2NCOA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017167638-A1 NON-AQUEOUS ELECTROLYTES AND USES THEREOF SONY CORPORATION (JP) 2017-10-05 WO disclosed
US-20110071113-A1 Thiazole Derivatives and Use Thereof MERCK SERONO SA (CH) 2011-03-24 US disclosed
US-7888379-B2 N-[5-(5-formyl-2-thienyl)-4-methyl-1,3-thiazol-2-yl]acetamide; autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer MERCK SERONO SA (CH) 2011-02-15 US disclosed
US-20080200463-A1 Thiazole Derivatives and Use Thereof LABORATOIRES SERONO SA (CH) 2008-08-21 US disclosed
EP-1888573-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2008-02-20 EP disclosed
WO-2006125807-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200463-A1 Thiazole Derivatives and Use Thereof PDGFRB, PDGFRA, TEC LMNA 4765/4885NPSR1 1930/4885PPARG 310/4885
US-20110071113-A1 Thiazole Derivatives and Use Thereof PDGFRB, PDGFRA, TEC LMNA 4765/4885NPSR1 1930/4885PPARG 310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.